docetaxel + apalutamide + androgen deprivation therapy

This combination regimen, often referred to as "triplet therapy," consists of the taxane chemotherapy agent docetaxel, the second-generation androgen receptor inhibitor apalutamide, and systemic androgen deprivation therapy (ADT). It is the subject of the Phase III ASPIRE trial (A031902), conducted by the Alliance for Clinical Trials in Oncology. The regimen is specifically designed for patients with metastatic castration-sensitive prostate cancer (mCSPC). Docetaxel works by stabilizing microtubules and inhibiting cell division, while apalutamide binds directly to the androgen receptor (AR) to inhibit nuclear translocation and DNA binding. ADT serves as the backbone of treatment by suppressing circulating testosterone levels. The ASPIRE trial evaluates whether the addition of docetaxel to the standard doublet of apalutamide and ADT improves clinical outcomes such as overall survival and progression-free survival.

Brand names

ErleadaTaxotere

Other names

androgen therapy-Alliance for Clinical Trials in Oncology-metastatic castrate-sensitive prostate cancerADT + apalutamide + docetaxeltriplet therapy